Elutia (NASDAQ:ELUT) Announces Quarterly Earnings Results, Beats Estimates By $1.62 EPS

Elutia (NASDAQ:ELUT) announced its quarterly earnings results on Wednesday. The company reported $1.48 EPS for the quarter, beating the consensus estimate of ($0.14) by $1.62, FiscalAI reports. The firm had revenue of $3.30 million for the quarter, compared to analysts’ expectations of $3.30 million.

Here are the key takeaways from Elutia’s conference call:

• Elutia submitted NXT-41 to the FDA and expects clearance in the second half of 2026, with the drug‑eluting NXT-41X targeted for clearance toward the end of H1 2027 and a planned commercial launch in H2 2027.
• NXT-41X combines the NXT-41 biologic matrix with rifampin and minocycline to deliver uniform, local antibiotic coverage for roughly 30 days, a design intended to materially reduce postoperative breast‑reconstruction infections (management cited potential ≥~50% reductions versus current ad‑hoc local approaches).
• Management strengthened the balance sheet by selling BioEnvelope to Boston Scientific for $88 million, paying off senior debt, and ending Q4 with $44.4 million in cash plus escrow, which they say funds development through approval and commercialization.
• The company is exploring strategic options for SimpliDerm — a standalone acellular dermal product with reimbursement covering ~100 million lives — which could unlock value but would also remove an operating asset used today.
• Elutia says its Gaithersburg manufacturing facility can support ~$120 million in revenue on one shift, and the company has added commercial leadership and active KOL/VAC engagement to prepare for commercialization.

Elutia Stock Performance

ELUT stock remained flat at $1.09 during trading on Wednesday. 183,194 shares of the company traded hands, compared to its average volume of 270,727. The stock has a market cap of $46.54 million, a PE ratio of -1.18 and a beta of 0.65. Elutia has a 12-month low of $0.50 and a 12-month high of $3.46. The stock has a 50 day moving average of $0.96 and a 200 day moving average of $0.98.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Elutia in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Elutia presently has an average rating of “Hold” and an average target price of $6.00.

Insiders Place Their Bets

In related news, Director Kevin Rakin bought 70,000 shares of Elutia stock in a transaction dated Friday, January 30th. The shares were bought at an average cost of $1.06 per share, for a total transaction of $74,200.00. Following the completion of the transaction, the director owned 196,120 shares of the company’s stock, valued at approximately $207,887.20. This trade represents a 55.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Matthew Ferguson purchased 60,000 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were bought at an average cost of $0.53 per share, for a total transaction of $31,800.00. Following the completion of the purchase, the chief financial officer directly owned 447,110 shares of the company’s stock, valued at $236,968.30. The trade was a 15.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 255,500 shares of company stock valued at $189,605 over the last ninety days. Insiders own 27.60% of the company’s stock.

Hedge Funds Weigh In On Elutia

Institutional investors have recently modified their holdings of the stock. Deerfield Management Company L.P. bought a new stake in Elutia during the third quarter worth $1,221,000. XTX Topco Ltd acquired a new position in Elutia during the fourth quarter worth approximately $71,000. Renaissance Technologies LLC increased its holdings in shares of Elutia by 64.7% in the fourth quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock valued at $71,000 after purchasing an additional 40,123 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Elutia during the third quarter worth approximately $50,000. Finally, Virtu Financial LLC bought a new stake in Elutia in the 3rd quarter valued at $26,000. 74.03% of the stock is currently owned by institutional investors and hedge funds.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.